<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04415008</url>
  </required_header>
  <id_info>
    <org_study_id>IHBD-IIT2020008</org_study_id>
    <nct_id>NCT04415008</nct_id>
  </id_info>
  <brief_title>Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia</brief_title>
  <official_title>A Prospective, Multicenter, Single Arm Clinical Study to Evaluate Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>wang, jianxiang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Hematology &amp; Blood Diseases Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute myeloid leukemia is a heterogenous hematological malignancy, characterized by different&#xD;
      cytogenetic or molecular features. CEBPA double mutation acute myeloid leukemia （CEBPAdm&#xD;
      AML）has favourite prognosis, especially in younger adult patients. But cumulative incidence&#xD;
      of relapse of this group patients is still high, so the treatment options need to be&#xD;
      optimized urgently.HAD(homoharringtonine(HHT)+cytarabine+daunorubicin) with intermediate dose&#xD;
      cytarabine improved the survival of AML, especially in patients with CEBPA double mutation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this phase 2 study, 50 patients will be enrolled and treated with HAD induction regimen.&#xD;
      High dose cytarabine will be given after complete remission achieved. The primary endpoint&#xD;
      was relapse-free survival. Genetic mutations and measurable residual disease (MRD) will be&#xD;
      detected at diagnosis and after chemotherapy. The risk stratification according to genetic&#xD;
      mutations and MRD will also be explored.&#xD;
&#xD;
      induction chemotherapy:HHT 2mg/m2/d,day 1-7 cytarabine 100mg/m2/d, day1-4；1g/m2 /q12h ，day5-7&#xD;
      DNR 40mg/m2/d，day 1-3 re-induction chemotherapy:IDA 10mg/m2，day 1-3 cytarabine 100mg/m2，day&#xD;
      1-7 CTX 350mg/m2，day 2，day 5 consolidation chemotherapy: high dose cytarabine&#xD;
      3g/m2/Q12h,day1-3,for three cycles&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>relapse free survival</measure>
    <time_frame>5 years</time_frame>
    <description>survival from complete remission to relapse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete remission rate</measure>
    <time_frame>2.5 years</time_frame>
    <description>incidence of complete remission after induction chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>early mortality</measure>
    <time_frame>2.5 years</time_frame>
    <description>death during 30 days from induction chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>duration from enrollment to death or loss of followup</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RFS cencored at stem cell transplantation</measure>
    <time_frame>5 years</time_frame>
    <description>RFS cencored at the date of stem cell transplantation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>CEBPA Double Mutation</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>prospective, open-label, multicenter,single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HAD induction with intermediate dose cytarabine</intervention_name>
    <description>daunorubicin,cytarabine,homoharringtonine</description>
    <arm_group_label>treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  newly-diagnosed of acute myeloid leukemia except acute promyelocytic leukemia&#xD;
&#xD;
          -  with CEBPA double mutation&#xD;
&#xD;
          -  age≥ 14 years and&lt;55 years，male or female&#xD;
&#xD;
          -  ECOG-PS score 0-2&#xD;
&#xD;
          -  laboratory tests（within 7 days before chemotherapy）&#xD;
&#xD;
               1. serum total bilirubin≤1.5xULN；&#xD;
&#xD;
               2. serum AST and ALT≤2.5xULN&#xD;
&#xD;
               3. serum creatinine≤2xULN；&#xD;
&#xD;
               4. cardiac enzymes≤2xULN&#xD;
&#xD;
               5. ejection fraction &gt;50% by ECHO。&#xD;
&#xD;
          -  written informed consent。&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  subject has received remission induction chemotherapy&#xD;
&#xD;
          -  secondary AML&#xD;
&#xD;
          -  with other hematological malignancy&#xD;
&#xD;
          -  with other tumors(needing treatment)&#xD;
&#xD;
          -  pregnant or lactating women&#xD;
&#xD;
          -  active heart diseases&#xD;
&#xD;
          -  severe active infection&#xD;
&#xD;
          -  unfit for enrollment evaluated by investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>HBDH</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Wei</last_name>
      <phone>86-22-23909020</phone>
      <email>weihui@ihcams.ac.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 31, 2020</study_first_submitted>
  <study_first_submitted_qc>June 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Hematology &amp; Blood Diseases Hospital</investigator_affiliation>
    <investigator_full_name>wang, jianxiang</investigator_full_name>
    <investigator_title>Director of leukemia center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

